Cytokines - major molecular messengers orchestrate between inflammation and cancer

Inflammation is the defensive mechanism against physical or chemical or thermal or infectious agents. Acute inflammation is a protective mechanism against any noxious stimuli by various mediators such as cytokines, chemokines, enzymes, growth factors by inflammatory cells. If the inflammation is aggrevated chronically, smouldering inflammation results in release of inflammatory mediators such as cytokines, chemokines, growth factors, proteolytic enzymes, from innate and adaptive immune cells results in tumor initiation, tumor promotion and tumor progression. Cytokines are intercellular molecular messengers between immune cells and cancer cells, synthesized from immune cells and stromal cells activate transcription factors bring about tumor progression by cell proliferation, cell survival, angiogenesis, genomic instability, epithelial to mesenchymal transition, invasion and metastasis. This article briefs about the role of IL-1, TNF-α, IL-6, IL-8, IL-10, TGF- β, and IL-17 cytokines in progression of cancer.

___

[1] Canas N, Delgado H, Silva V, Pinto AR, Sousa S, Simões R, et al. The electroclinical spectrum, etiologies, treatment and outcome of nonconvulsive status epilepticus in the elderly. Epilepsy Behav 2017;79:53-7.
[2] Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012;17:3-23.
[3] Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia 1994;35:27-34.
[4] DeLorenzo RJ, Ko D, Towne AR, Garnett LK, Boggs JG, Waterhouse EJ, et al. Prediction of outcome in status epilepticus. Epilepsia 1997;38(suppl 8):210- 5.
[5] Riviello JJ Jr, Claassen J, LaRoche SM, Sperling MR, Alldredge B, Bleck TP, et al. Treatment of status epilepticus: an international survey of experts. Neurocrit Care 2013;18:193-200.
[6] Lempl Y, Eshel Y, Gilad R, Sarova-Pinchas I. Chloral hydrate in intractable status epilepticus. Ann Emerg Med 1990;19:674-6.
[7] Knake S, Gruener J, Hattemer K, Klein KM, Bauer S, Oertel WH, et al Intravenous levetiracetam in the treatment of benzodiazepine-refractory status epilepticus. J Neurol Neurosurg Psychiatry 2008;79:588-9.
[8] Agarwal P, Kumar N, Chandra R, Gupta G, Antony AR, Garg N. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure 2007;16:527-32.
[9] Mori K, Ito H, Toda Y, Hashimoto T, Miyazaki M, Saijo T, et al. Successful management of intractable epilepsy with lidocaine tapes and continuous subcutaneous lidocaine infusion. Epilepsia 2004;45:1287-90.